Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 19 de 19
1.
Egypt J Immunol ; 31(2): 1-9, 2024 Apr.
Article En | MEDLINE | ID: mdl-38615199

T helper 17 (Th17) cells have been reported to be the most powerful factor in autoimmune disorder pathogenesis, which points to the Th17 master cytokine, interleukin (IL)-17A, as the crucial mediator. We aimed to determine the impact of IL-17A polymorphism in the -197 G/A promoter region on level of IL-17 and intensity of rheumatoid arthritis (RA) disease symptoms. This case-control study was conducted at the Department of Clinical Rheumatology of Aswan university Hospital and included 35 people suffering RA and 30 volunteer controls, matched for age and sex. Rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, erythrocyte sedimentation rate (ESR), serum IL-17, and C-reactive protein (CRP) were measured in the RA patient group. Restriction fragment length polymorphism (RFLP) was conducted by polymerase chain reaction (PCR) amplicon obtained by IL-17A -197 G /A primers. Of the 35 RA patients, RF was positive in 33 (94.29%) and anti-CCP antibodies in 25 (71.43%), CRP in 31 (88.57%). Of the 35 RA patients, 5 (14.29%) patients carried the G/G genotype, 18 (51.43%) G/A and 12 (34.29%) A/A. IL-17 serum level was significantly greater in the more active RA (DAS28 >5.1) group than the less active (DAS28 ≤5.1) group. Of the RA patients carrying wild type G/G genotype, 60% had more active disease (DAS 28> 5.1), as compared to those with lower activity (DAS 28 ≤5.1), 40% carried the wild type G/G genotype. In conclusion, the study findings imply that IL-17A gene polymorphism is connected to RA clinical severity rather than with RA susceptibility.


Arthritis, Rheumatoid , Interleukin-17 , Humans , Anti-Citrullinated Protein Antibodies , Arthritis, Rheumatoid/genetics , C-Reactive Protein/chemistry , Case-Control Studies , Interleukin-17/blood , Interleukin-17/chemistry , Interleukin-17/genetics , Patient Acuity , Polymorphism, Genetic , Rheumatoid Factor , Promoter Regions, Genetic
2.
Inflammopharmacology ; 31(4): 1929-1949, 2023 Aug.
Article En | MEDLINE | ID: mdl-37131046

Rheumatoid arthritis (RA) is an autoimmune chronic inflammatory disease associated with oxidative stress that causes excruciating pain, discomfort, and joint destruction. Ebselen (EB), a synthesized versatile organo-selenium compound, protects cells from reactive oxygen species (ROS)-induced injury by mimicking glutathione peroxidase (GPx) action. This study aimed to investigate the antioxidant and anti-inflammatory effects of EB in an arthritic irradiated model. This goal was achieved by subjecting adjuvant-induced arthritis (AIA) rats to fractionated whole body γ-irradiation (2 Gy/fraction once per week for 3 consecutive weeks, for a total dose of 6 Gy) and treating them with EB (20 mg/kg/day, p.o) or methotrexate (MTX; 0.05 mg/kg; twice/week, i.p) as a reference anti-RA drug. The arthritic clinical signs, oxidative stress and antioxidant biomarkers, inflammatory response, expression of NOD-like receptor protein-3 (NLRP-3) inflammasome, receptor activator of nuclear factor κB ligand (RANKL), nuclear factor-κB (NF-κB), apoptotic indicators (caspase 1 and caspase 3), cartilage integrity marker (collagen-II), and histopathological examination of ankle joints were assessed. EB notably improved the severity of arthritic clinical signs, alleviated joint histopathological lesions, modulated oxidative stress and inflammation in serum and synovium, as well as reduced NLRP-3, RANKL, and caspase3 expression while boosting collagen-II expression in the ankle joints of arthritic and arthritic irradiated rats with comparable potency to MTX. Our findings suggest that EB, through its antioxidant and anti-inflammatory properties, has anti-arthritic and radioprotective properties in an arthritic irradiated model.


Arthritis, Experimental , Arthritis, Rheumatoid , Rats , Animals , NLR Family, Pyrin Domain-Containing 3 Protein , Antioxidants/pharmacology , Antioxidants/therapeutic use , RANK Ligand/metabolism , Arthritis, Rheumatoid/metabolism , Arthritis, Experimental/drug therapy , Arthritis, Experimental/pathology , Methotrexate/therapeutic use , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Collagen
3.
Res Pharm Sci ; 18(2): 219-230, 2023 Apr.
Article En | MEDLINE | ID: mdl-36873275

Background and purpose: Obesity is a public health problem and the existence of beige adipocytes has got interested as a potential therapeutic involvement for obesity and obesity-associated diseases. Adipose tissue M1 macrophage inhibition, also, has a vital role in obesity via down-regulating adipose tissue inflammation and the use of natural compounds such as oleic acid with exercise has been proposed. The present study aimed to evaluate the possible effects of oleic acid and exercise on diet-induced thermogenesis and obesity in rats. Experimental approach: Wister albino rats were categorized into six groups. Group I: normal control, group II: oleic acid group (9.8 mg/kg; orally), group III: high-fat diet (HFD), group IV: HFD plus oleic acid, group V: HFD plus exercise training, group VI: HFD plus exercise training and oleic acid. Findings/Results: Oleic acid administration and/or exercise significantly decreased body weight, TG, and cholesterol, as well as elevated HDL levels. Furthermore, oleic acid administration and/or exercise reduced serum MDA, TNF-α, and IL-6 levels, elevated the levels of GSH and irisin, increased the expression of UCP1, CD137, and CD206, and reduced CD11c expression. Conclusion and implications: Oleic acid supplementation and/or exercise could be used as therapeutic agents for treating obesity via its antioxidant and anti-inflammatory activities, stimulation of beige adipocyte differentiation, and macrophage M1 inhibition.

4.
Inflammopharmacology ; 31(3): 1361-1372, 2023 Jun.
Article En | MEDLINE | ID: mdl-36877411

Cyclophosphamide (CP) is a chemotherapeutic agent that causes pulmonary damage by generating free radicals and pro-inflammatory cytokines. Pulmonary damage has a high mortality rate due to the severe inflammation and edema occurred in lung. PPARγ/Sirt 1 signaling has been shown to be cytoprotective effect against cellular inflammatory stress and oxidative injury. Protocatechuic acid (PCA) is a potent Sirt1 activator and exhibits antioxidant as well as anti-inflammatory properties. The current study aims to investigate the therapeutic impacts of PCA against CP-induced pulmonary damage in rats. Rats were assigned randomly into 4 experimental groups. The control group was injected with a single i.p injection of saline. CP group was injected with a single i.p injection of CP (200 mg/kg). PCA groups were administered orally with PCA (50 and 100 mg/kg; p.o.) once daily for 10 consecutive days after CP injection. PCA treatment resulted in a significant decrease in the protein levels of MDA, a marker of lipid peroxidation, NO and MPO along with a significant increase in GSH and catalase protein levels. Moreover, PCA downregulated anti-inflammatory markers as IL-17, NF-κB, IKBKB, COX-2, TNF-α, and PKC and upregulated cytoprotective defenses as PPARγ, and SIRT1. In addition, PCA administration ameliorated FoxO-1 elevation, increased Nrf2 gene expression, and reduced air alveoli emphysema, bronchiolar epithelium hyperplasia and inflammatory cell infiltration induced by CP. PCA might represent a promising adjuvant to prevent pulmonary damage in patients receiving CP due to its antioxidant and anti-inflammatory effects with cytoprotective defenses.


Antioxidants , Peroxisome Proliferators , Rats , Animals , Antioxidants/pharmacology , Antioxidants/metabolism , Peroxisome Proliferators/pharmacology , Sirtuin 1/metabolism , PPAR gamma/metabolism , Cyclophosphamide/adverse effects , Lung , Oxidative Stress , Anti-Inflammatory Agents/pharmacology
5.
Life Sci ; 314: 121317, 2023 Feb 01.
Article En | MEDLINE | ID: mdl-36566881

AIMS: Glycyrrhizin (Glyc) is a saponin triterpenoid that has signified its efficacy against Huntington's disease (HD). Nonetheless, its mechanism has not been fully clarified. Accordingly, this study was designed to evaluate the plausible mechanism of action of Glyc against 3-nitropropionic acid (3-NP)-induced HD. MAIN METHODS: Rats were treated with Glyc (50 mg/kg, i.p.) for 3 weeks and 3-NP (10 mg/kg, i.p.) was administered at the latter 2 weeks alongside to induce HD. KEY FINDINGS: Animals exposed to 3-NP revealed a reduction in body weight, neurobehavioral abnormalities, and various deleterious effects related to overexpression of HMGB1 such as oxidative stress, apoptosis, and inflammation. Promisingly, Glyc administration provided valuable effects by reversing the decline in body weight with improved neurobehavioral deficits. Ameliorating oxidative stress via restoring GSH, SOD, and Nrf2 alongside with MDA suppression was evident. Furthermore, Glyc switched the HMGB1/TLR4/NF-κB p65 signaling off, reduced IL-6, IL-ß, TNF-α, caspase-3, and increased Bcl-2 as well as BDNF. All these beneficial effects were mirrored by a better histopathological picture upon using Glyc that suppressed gliosis by reducing GFAP expression as observed in the immunohistochemistry results. SIGNIFICANCE: Accordingly, the current study demonstrated a promising neuroprotective effect of Glyc against experimentally induced HD through alleviating deleterious events by diverse mechanisms.


HMGB1 Protein , Huntington Disease , Rats , Animals , NF-kappa B/metabolism , Glycyrrhizic Acid/pharmacology , Toll-Like Receptor 4/metabolism , HMGB1 Protein/metabolism , Inflammation/drug therapy , Inflammation/prevention & control , Huntington Disease/metabolism , Oxidative Stress , Body Weight , Apoptosis
6.
Int Immunopharmacol ; 111: 109068, 2022 Oct.
Article En | MEDLINE | ID: mdl-35944459

BACKGROUND: Prodigiosin (PDG) is a microbial red dye with antioxidant and anti-inflammatory properties, although its effect on rheumatoid arthritis (RA) remains uncertain. Also, multiple doses of low dose γ- radiation (LDR) have been observed to be as a successful intervention for RA. Thus, the purpose of this study was to investigate the ameliorative potential of PDG and/or LDR on adjuvant-induced arthritis (AIA) in rats. METHODS: The anti-inflammatory and anti-arthritic effects of PDG and/or LDR were examined in vitro and in vivo, respectively. In the AIA model, the arthritic indexes, paw swelling degrees, body weight gain, and histopathological assessment in AIA rats were assayed. The impact of PDG (200 µg/kg; p.o) and/or LDR (0.5 Gy) on the levels of pro- and anti-inflammatory cytokines (IL-1ß, TNF-α, IL-6, IL-18, IL-17A, and IL-10) as well as the regulation of osteoprotegrin (OPG)/ receptor activator of nuclear factor κB ligand (RANKL)/ nuclear factor-κB (NF-κB)/MMP-13 pathways was determined. Methotrexate (MTX; 0.05 mg/kg; twice/week, i.p) was administered concurrently as a standard anti-arthritic drug. RESULTS: PDG and/or LDR markedly diminished the arthritic indexes, paw edema, weigh loss in AIA rats, alleviated the pathological alterations in joints, reduced the levels of pro-inflammatory cytokines IL-1ß, TNF-α, IL-6, IL-18, IL-17A, and RANKL in serum and synovial tissues, while increasing anti-inflammatory cytokines IL-10 and OPG levels. Moreover, PDG and/or LDR down-regulated the expression of RANKL, NF-κBp65, MMP13, caspase-3, and decreased the RANKL/OPG ratio, whereas OPG and collagen II were enhanced in synovial tissues. CONCLUSION: PDG and/or LDR exhibited obvious anti-RA activity on AIA.


Arthritis, Experimental , Arthritis, Rheumatoid , Prodigiosin , Animals , Anti-Inflammatory Agents/therapeutic use , Arthritis, Experimental/therapy , Arthritis, Rheumatoid/therapy , Cytokines/metabolism , Interleukin-10/metabolism , Interleukin-17/metabolism , Interleukin-18/metabolism , Interleukin-6/metabolism , Matrix Metalloproteinase 13/metabolism , Methotrexate/therapeutic use , NF-kappa B/metabolism , Prodigiosin/therapeutic use , Rats , Tumor Necrosis Factor-alpha/metabolism
7.
Eur J Pharmacol ; 932: 175217, 2022 Oct 15.
Article En | MEDLINE | ID: mdl-36007603

Modulation of the inflammasome NLRP3 and SIRT1 are new combat strategy for brain injury protection. The inflammasome activates proinflammatory cytokines releasing interleukin-1ß and interleukin-18 which in turn affect the toxins release from immune cells. In addition, SIRT1 controls many biological functions, such as immune response and oxidative stress. Protocatechuic has versatile biological activities and possesses antioxidant, anti-inflammatory and neuroprotective effects. So this work aims to study immunomodulatory effect of protocatechuic acid on cyclophosphamide chemotherapy drug-induced brain injury via modulation of inflammosomes NLRP3 and SIRT1. Rats were randomly assigned to four experimental groups. Normal control group was injected with a single i.p injection of saline. Cyclophosphamide group was injected with a single i.p injection of cyclophosphamide (200 mg/kg). Protocatechuic acid groups were orally administered (50 &100 mg/kg) once daily for 10 consecutive days after cyclophosphamide injection. Protocatechuic acid administration exhibited improvements of the cognition function and memory, a reduction in brain contents of MDA, NLRP3, IL-1 ß, NF-κB, IKBKB and Galectin 3 and an elevation of GSH and SIRT1 compared to cyclophosphamide group. In addition, protocatechuic acid administration ameliorated the elevation of caspase 3 and iNOS gene expression and alleviated the neuron degeneration caused by cyclophosphamide. In conclusion, the therapeutic action of protocatechuic acid and its cellular and molecular mechanisms are new insights against various human ailments, especially, neurodegenerative disease as brain injury induced by cyclophosphamide chemotherapy drug in rats through modulation of inflammosomes NLRP3 and SIRT1.


Brain Injuries , Neurodegenerative Diseases , Neuroprotective Agents , Animals , Anti-Inflammatory Agents/therapeutic use , Antioxidants/metabolism , Brain Injuries/chemically induced , Brain Injuries/drug therapy , Caspase 3 , Cyclophosphamide/adverse effects , Cytokines/metabolism , Galectin 3 , Humans , Hydroxybenzoates , I-kappa B Kinase , Immunity , Inflammasomes/metabolism , Interleukin-18 , Interleukin-1beta/metabolism , NF-kappa B/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Neurodegenerative Diseases/drug therapy , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Rats , Sirtuin 1/metabolism
8.
Neuropsychiatr Dis Treat ; 17: 3471-3482, 2021.
Article En | MEDLINE | ID: mdl-34880616

BACKGROUND: COVID-19 is a complex multisystem disease comprising multiple organ dysfunctions including neurologic manifestations. Some COVID-19 patients may present neurologic symptoms as the initial presentations of the disease. OBJECTIVE: We aim at investigating the frequency and the predictors of neurological manifestations in patients with confirmed COVID-19. METHODS: A retrospective cross-sectional single-center study analyzed COVID-19 positive patients with neurological manifestations from March to June 2020, in Aswan Governorate, Egypt. Demographic data, clinical, radiological and laboratory findings, comorbidities, and treatments were collected and analyzed. RESULTS: Out of the 905 confirmed COVID-19 patients; 422 patients (46.6%) had neurological manifestations and fulfilled the study inclusion criteria, 223 patients (52.8%) had central neurological disorders (CNS), 107 (25.4%) had peripheral neurological disorders (PNS), and 92 (21.8%) patients had non-specific neurological disorders. Age >50 years, diabetes mellitus, CORAD> III and smoking were predictors for neurological system affection. CONCLUSION: COVID-19 infection has been associated with numerous neurological deficits, especially in elderly patients. Central nervous system disorders were the most prevalent deficit with predominance of cerebrovascular events.

9.
Can J Physiol Pharmacol ; 99(3): 332-347, 2021 Mar.
Article En | MEDLINE | ID: mdl-32721224

Hepatic encephalopathy depicts the cluster of neurological alterations that occur during acute or chronic hepatic injury. Hyperammonemia, inflammatory injury, and oxidative stress are the main predisposing factors for the direct and indirect changes in cerebral metabolism causing encephalopathy. The aim of this study was to evaluate the possible synergistic effect between aminoguanidine (AG; 100 mg/kg, p.o.) and l-carnosine (CAR; 200 mg/kg, p.o.) on hepatic encephalopathy that was induced by thioacetamide (TAA; 100 mg/kg, i.p.) administered three times weekly for six weeks. Behavioral changes, biochemical parameters, histopathological analysis, and immunohistochemical and ultrastructural studies were conducted 24 h after the last treatment. Combining AG with CAR improved TAA-induced locomotor impairment and motor incoordination evidenced by reduced locomotor activity and decline in motor skill performance, as well as ameliorated cognitive deficits. Moreover, both drugs restored the levels of serum hepatic enzymes and serum and brain levels of ammonia. In addition, the combination significantly modulated hepatic and brain oxidative stress biomarkers, inflammatory cytokines, and cleaved caspase-3 expression. Furthermore, they succeeded in activating nuclear erythroid 2-related factor 2 (Nrf2) expression and heme oxygenase-1 (HO-1) activity and ameliorating markers of hepatic encephalopathy, including hepatic necrosis and brain astrocyte swelling. This study shows that combining AG with CAR exerted a new intervention for hepatic and brain damage in hepatic encephalopathy due to their complementary antioxidant, anti-inflammatory effects and hypoammonemic effects via Nrf2/HO-1 activation and NO inhibition.


Carnosine/therapeutic use , Guanidines/therapeutic use , Hepatic Encephalopathy/prevention & control , Thioacetamide , Ammonia/metabolism , Animals , Behavior, Animal , Brain/pathology , Brain Chemistry/drug effects , Drug Synergism , Hepatic Encephalopathy/chemically induced , Hepatic Encephalopathy/psychology , Liver/pathology , Liver Function Tests , Male , Motor Activity/drug effects , Motor Skills/drug effects , Rats , Rats, Wistar
10.
Life Sci ; 266: 118882, 2021 Feb 01.
Article En | MEDLINE | ID: mdl-33310046

AIMS: Cilostazol (Cilo), a phosphodiesterase-III inhibitor, has signified its efficacy against different ischemia/reperfusion (IS/RE) models. Nevertheless, it has not fully illuminated its potential effect against intestinal IS/RE-induced lung injury. Consequently, the study was fashioned to evaluate the feasible mechanism of action of Cilo against intestinal IS/RE-induced lung injury. MAIN METHODS: Wistar rats were treated with Cilo (0.1 g/kg, p.o.) or with a vehicle for 14 days prior to IS/RE, induced by clamping of the superior mesenteric artery for 30 min with subsequent clamp removal for 2 h. KEY FINDINGS: The mechanistic study disclosed that Cilo protected the two studied organs, viz., lung, and intestine partially by intensifying the expression/content of PPAR-γ accompanied by reducing the expression/content of NF-қB-p65 and STAT3. In addition to normalizing MDA, iNOS, and NOx, the Cilo antioxidant power was confirmed by intensifying tissues content of the total antioxidant capacity. With regard to the anti-inflammatory effect, Cilo reduced the effects of TNF-α, IL-6, and ICAM-1, which were reflected in MPO activity. Furthermore, Cilo had an anti-apoptotic attribute demonstrated by enhancing Bcl-2 content and lessening caspase-3 level. SIGNIFICANCE: Cilo provided conceivable protective mechanisms to modulate events concomitant with mesenteric IS/RE partly by modulating oxidative stress, inflammation, and apoptosis feasibly via the participation of PPAR-γ, STAT3, and NF-κB p65 signaling pathways.


Cilostazol/pharmacology , Lung Diseases/prevention & control , Mesenteric Ischemia/complications , NF-kappa B/metabolism , PPAR gamma/metabolism , Reperfusion Injury/complications , STAT3 Transcription Factor/metabolism , Animals , Bronchodilator Agents/pharmacology , Gene Expression Regulation , Lung Diseases/etiology , Lung Diseases/metabolism , Lung Diseases/pathology , Male , NF-kappa B/genetics , Oxidative Stress , PPAR gamma/genetics , Rats , Rats, Wistar , STAT3 Transcription Factor/genetics , Signal Transduction
11.
Infect Drug Resist ; 13: 543-552, 2020.
Article En | MEDLINE | ID: mdl-32110064

AIM: This study aimed to describe the inhibitory activity of cell-free supernatants (CFS) of lactobacilli against extended-spectrum ß-lactamase (ESBL)-producing Klebsiella pneumoniae (K pneumoniae) and Pseudomonas aeruginosa (P aeruginosa). MATERIAL AND METHODS: Pathogenic clinical strains of K pneumoniae and P aeruginosa were isolated from urine samples and selected for investigation. Anti-bacterial activities of the CFS of lactobacilli were assessed by agar well diffusion, MTT assay, as well as time-kill tests. In addition, the antibiofilm characteristics were analyzed by the microplate method against fresh and 24 h-old biofilms. The ability of CFS to interfere with bacterial invasion was analyzed by flow cytometry. RESULTS: Although all tested strains were ESBL producers and showed a multidrug-resistant phenotype, the CFS displayed a high anti-ESBL activity with inhibition zone diameters greater than 13 mm in the agar well diffusion assays against both pathogens. The growth kinetics of K pneumoniae and P aeruginosa were dramatically decreased in the presence of the CFS. The CFS not only inhibited the biofilm formation by these pathogens but also was able to remove the 24-h formed biofilms. The invasion abilities of FITC-labelled K pneumoniae decreased from 30.3%±7 to 15.4%±5 and invasion of FITC-labelled P aeruginosa was reduced from 36.9%±7 to 25.2%±5. CONCLUSION: CFS of lactobacilli exhibit anti-ESBL activities, which suggests its potential application for controlling or preventing colonization of infections caused by ESBL-producing bacteria.

12.
Mini Rev Med Chem ; 19(5): 437-447, 2019.
Article En | MEDLINE | ID: mdl-29595108

BACKGROUND: A novel series of fused imidazole was prepared from the reaction of 2- bromoacetyl-3-phenyl-1,3,4-thiadiazole with various heterocyclic amines under microwave irradiation. The structures of all the novel products were elucidated based on the elemental analysis and spectral data. RESULTS: In addition, the biological activity of the newly synthesized compounds was evaluated and the results obtained indicate their potency as anti-inflammatory, analgesic and anti- ulcer agents. CONCLUSION: The binding mechanism of the most active compounds was studied using MOE to analyze the molecular interactions.


Analgesics/chemistry , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Ulcer Agents/chemistry , Thiadiazoles/chemistry , Analgesics/chemical synthesis , Analgesics/pharmacology , Analgesics/therapeutic use , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anti-Ulcer Agents/chemical synthesis , Anti-Ulcer Agents/pharmacology , Anti-Ulcer Agents/therapeutic use , Chemistry Techniques, Synthetic/methods , Cyclooxygenase 2/metabolism , Edema/drug therapy , Edema/metabolism , Humans , Imidazoles/chemical synthesis , Imidazoles/chemistry , Imidazoles/pharmacology , Imidazoles/therapeutic use , Microwaves , Molecular Docking Simulation , Rats , Stomach Ulcer/drug therapy , Stomach Ulcer/metabolism , Thiadiazoles/chemical synthesis , Thiadiazoles/pharmacology , Thiadiazoles/therapeutic use
13.
Egypt J Immunol ; 25(1): 143-151, 2018 Jan.
Article En | MEDLINE | ID: mdl-30243006

Hypercoagulability in patients with primary Antiphospholipid syndrome (APS) predisposes to high rates of thromboembolic events and restenosis of the coronaries causing significant morbidity and mortality. Although the association between the APS and Acute Myocardial infraction (AMI) is very rare about 4%. Treatment of patients with APS represent a clinical challenge. Current study was designed to investigate the correlation between antiphospholipid antibodies (aPL) in prediction of the complication-associated AMI in Aswan governorate. Fifty AMI patients were compared to thirty controls. Serum aPLs was assessed using commercial ELISA kits. In patients; data revealed that mean Lupus anticoagulant was 59.2 U/mL, IgM and IgG anticardiolipin was 1.14 U/mL and 1.26 U/mL respectively. In addition the mean of antiphosphatidyl inositol (aPI) was 11.68 U/mL. On follow-up; Lupus and aCA IgM showed weak correlation with cases that showed further complications, while aCA-IgG showed protective effects (P=0.001/ r=-0.463) and aPI-IgM moderate correlation with the complications (P=0.048/ r=0.281). It's concluded that aCAs play distinct roles in the pathogenesis of AMI reduced levels of aCA-IgG has protective effects while the aCA-IgM indicate a poor prognosis, and that aPI is a good marker for prediction of recurrence of cardiovascular events among patients.


Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/complications , ST Elevation Myocardial Infarction/blood , Antibodies, Anticardiolipin/blood , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Prognosis , ST Elevation Myocardial Infarction/diagnosis
14.
Mini Rev Med Chem ; 18(16): 1409-1421, 2018.
Article En | MEDLINE | ID: mdl-29600758

BACKGROUND: Microwave assisted reactions offer a considerable advantages over conventional method reactions because the former results in substantial rate enhancement in a wide range of organic reactions. OBJECTIVE: we interested herein to prepare new anti-inflammatory and analgesic agents analogues to Indomethacin in short reaction time by using microwaves irradiation. METHOD: Synthesis of new hydrazonoindolines having thiazole moiety under microwave irradiation were achieved via the reaction of hydrazonoyl chlorides or halogenated active methylene derivatives with thiosemicarbazone derivatives. Also, the utility of the versatile indoline-2,3-dione derivatives in the design of new multifunctional building blocks using condensation with hydrazine derivatives was demonstrated. RESULTS: All products were formed in short reaction time and high yield. The information derived from the spectral data of the formed compounds was confirmed their structures. Also, the analgesic and antiinflammatory activities of the designed derivatives were screened and the results obtained indicated that six derivatives 4g, 9b, 4c, 10b, 4d and 11a revealed the highest anti-inflammatory and analgesic effects. CONCLUSION: we succeeded in this context to design and synthesis of new anti-inflammatory and analgesic agents analogues to Indomethacin in short reaction time and with high yield.


Analgesics/chemistry , Analgesics/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Indoles/chemistry , Indoles/pharmacology , Indomethacin/analogs & derivatives , Indomethacin/pharmacology , Animals , Drug Evaluation, Preclinical , Indomethacin/chemical synthesis , Male , Mice , Molecular Docking Simulation , Rats, Sprague-Dawley , Structure-Activity Relationship
15.
Eur J Pharmacol ; 822: 168-176, 2018 Mar 05.
Article En | MEDLINE | ID: mdl-29355562

Even though cilostazol was assessed before in several models of atherosclerosis, so far its full systematic effect as a natural anti-inflammatory and anti-apoptotic mediator in the protection of liver damage and complication has not been fully clarified, which is the target of this study. For that purpose, we examined the protective effect of cilostazol (10 and 5mg/kg, p.o. b.wt.) in an acute hepatic injury model by orally injecting it for 3 weeks prior to a single dose of TAA (300mg/kg, i.p) injection. Ursodeoxycholic acid was used as a standard drug (50mg/kg, p.o. b.wt.). After injection of thioacetamide by 48hr, rats were sacrificed. On the serum biochemical level, cilostazol ameliorated the thioacetamide consequence, where it presented a significant enhancement in the liver enzymes activities [Aspartate aminotransferase (AST) & Alanine aminotransferase (ALT)]. On the other hand, at the tissue level (Liver), it revealed a significant improvement in pro-inflammatory cytokines [Tumor necrosis factor alpha (TNF-α), Interleukin 1 beta (IL-1ß), Nuclear factor kappa B (NF-κB), NF-κB (P65/P50 nucleus translocation), caspase-3, cleaved caspase-3 & C-reactive protein (CRP)], redox level [Reduced glutathione (GSH) & Malondialdehyde (MDA)], histopathological findings, Reverse transcription polymerase chain reaction (RT-PCR) analysis (expression of TNF-α and NF-κB mRNA levels), and immunohistochemical reaction (caspase-3 & TNF-α). Obviously, the high dose of cilostazol (10mg/kg, p.o. b.wt.) displayed a more pronounced effect than its lower one and nearly equal to ursodeoxycholic acid in the most of the parameters. These results give a new awareness into the hopeful molecular mechanisms by which cilostazol attenuates several factors participated in the progression of liver damage.


Apoptosis/drug effects , Cytokines/metabolism , Liver/drug effects , Tetrazoles/pharmacology , Thioacetamide/toxicity , Animals , Antioxidants/metabolism , Biomarkers/metabolism , Caspase 3/metabolism , Cilostazol , Cytoprotection/drug effects , Gene Expression Regulation/drug effects , Inflammation/metabolism , Interleukin-1beta/metabolism , Liver/cytology , Liver/metabolism , Liver/physiology , Male , NF-kappa B/genetics , NF-kappa B/metabolism , Oxidative Stress/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
16.
Appl Physiol Nutr Metab ; 42(3): 243-249, 2017 Mar.
Article En | MEDLINE | ID: mdl-28177750

The present study aimed to evaluate the hepato-protective and neuro-protective activity of Co-enzyme Q10 (CoQ10) on non-alcoholic steatohepatitis (NASH) in albino rats induced by methionine and choline-deficient (MCD) diet. Rats were fed an MCD diet for 8 weeks to induce non-alcoholic steatohepatitis. CoQ10 (10 mg/(kg·day)-1) was orally administered for 2 consecutive weeks. Twenty-four hours after the last dose of the drug, the behavioral test, namely the activity cage test, was performed and the activity counts were recorded. Serum alanine transaminase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total/direct bilirubin, and albumin were valued to assess liver function. Moreover, hepatic cytokines interleukin-6 as well as its modulator nuclear factor kappa-light-chain-enhancer of activated B cells were determined. In addition, brain biomarkers, viz ammonia, nitric oxide, and brain-derived neurotrophic factor (BDNF), were measured as they are reliable indices to assess brain damage. Histopathological and immunohistochemical examination of brain proliferating cell nuclear antigen in brain and liver tissues were also evaluated. Results revealed that MCD-induced NASH showed impairment in the liver functions with an increase in the liver inflammatory markers. Moreover, NASH resulted in pronounced brain dysfunction as evidenced by hyper-locomotor activity, a decrease in the BDNF level, as well as an increase in the brain nitric oxide and ammonia contents. Oral treatment of MCD-diet-fed rats with CoQ10 for 14 days showed a marked improvement in all the assigned parameters. Finally, it can be concluded that CoQ10 has a hepatoprotective and neuroprotective role in MCD-diet-induced NASH in rats.


Diet , Non-alcoholic Fatty Liver Disease/drug therapy , Ubiquinone/analogs & derivatives , Alanine Transaminase/blood , Alkaline Phosphatase/blood , Ammonia/blood , Animals , Aspartate Aminotransferases/blood , Bilirubin/blood , Biomarkers/blood , Brain-Derived Neurotrophic Factor/blood , Choline/administration & dosage , Choline Deficiency/blood , Choline Deficiency/complications , Dose-Response Relationship, Drug , Interleukin-6/metabolism , Liver/drug effects , Liver/metabolism , Male , Methionine/administration & dosage , Methionine/blood , Methionine/deficiency , Neuroprotective Agents/pharmacology , Nitric Oxide/blood , Non-alcoholic Fatty Liver Disease/blood , Rats , Rats, Wistar , Serum Albumin/metabolism , Ubiquinone/pharmacology , gamma-Glutamyltransferase/blood
17.
Appl Physiol Nutr Metab ; 42(2): 181-192, 2017 Feb.
Article En | MEDLINE | ID: mdl-28092161

Even though ellagic acid has previously been valued in many models of cancer, so far its full mechanistic effect as a natural antiapoptotic agent in the prevention of type 2 diabetes complications has not been completely elucidated, which was the goal of this study. We fed albino rats a high-fat fructose diet (HFFD) for 2 months to induce insulin resistance/type 2 diabetes and then treated the rats with ellagic acid (10 mg/kg body weight, orally) and/or repaglinide (0.5 mg/kg body weight, orally) for 2 weeks. At the serum level, ellagic acid challenged the consequences of HFFD, significantly improving the glucose/insulin balance, liver enzymes, lipid profile, inflammatory cytokines, redox level, adipokines, ammonia, and manganese. At the tissue level (liver, pancreas, adipose tissue, and brain), ellagic acid significantly enhanced insulin signaling, autophosphorylation, adiponectin receptors, glucose transporters, inflammatory mediators, and apoptotic markers. Remarkably, combined treatment with both ellagic acid and repaglinide had a more pronounced effect than treatment with either alone. These outcomes give new insight into the promising molecular mechanisms by which ellagic acid modulates numerous factors induced in the progression of diabetes.


Apoptosis/drug effects , Carbamates/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Ellagic Acid/therapeutic use , Hypoglycemic Agents/therapeutic use , Insulin Resistance , Oxidative Stress/drug effects , Piperidines/therapeutic use , Animals , Antineoplastic Agents, Phytogenic/therapeutic use , Biomarkers/blood , Brain/drug effects , Brain/immunology , Brain/metabolism , Diabetes Mellitus, Type 2/immunology , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/physiopathology , Drug Therapy, Combination , Hyperglycemia/prevention & control , Inflammation Mediators/blood , Inflammation Mediators/metabolism , Intra-Abdominal Fat/drug effects , Intra-Abdominal Fat/immunology , Intra-Abdominal Fat/metabolism , Liver/drug effects , Liver/immunology , Liver/metabolism , Liver/physiopathology , Male , Neurons/drug effects , Neurons/immunology , Neurons/metabolism , Pancreas/drug effects , Pancreas/immunology , Pancreas/metabolism , Rats, Wistar
18.
Med Chem ; 13(3): 226-238, 2017.
Article En | MEDLINE | ID: mdl-27659119

BACKGROUND: Indane-1,3-dione, thiazole, bis-thiazole and thiadiazoles rings are very interested moieties in anti-inflammatory and analgesic drugs. OBJECTIVE: The goal of this work is to synthesize new derivatives of bis-thiazoles and bis-1,3,4- thiadiazoles for the investigation of their anti-inflammatory, anti-ulcerogenic and analgesic activities. METHODS: 1,1'-(1,2-phenylene)bis(3-phenylthiourea) (1) reacts with a number of N-aryl arenecarbohydrazonoyl chlorides 2 to give a series of new bis-1,3,4-thiadiazoles 4. Also, reaction of bisthiosemicarbazone of 1,3-indanedione 6 with another type of hydrazonoyl halides namely, N-aryl-2- oxapropanehydrazonoyl chlorides 7 and ethyl-(N-arylhydrazono)chloroacetate 8 in dioxane under reflux in the presence of triethylamine give the respective bis-thiazole derivatives 9 and 10, respectively. The products 9 and 10 can exist in five and seven tautomeric forms for each one. Their actual tautomeric forms were deduced based on electronic absorption data (UV / Vis spectra). Moreover, a series of novel bis-formazans 12 and 13 have been synthesized by reaction of 1,3-dihydrazono-2,3- dihydro-1H-indene (11) with both hydrazonoyl chlorides 7 and 8. RESULTS: The structure of all the novel products was deduced by elemental analysis and spectral data. In addition, the biological activity of the newly synthesized compounds was evaluated and the results obtained indicate their potency as anti-inflammatory, anti-ulcerogenic and analgesic agents. CONCLUSION: In this context, we synthesize new derivatives of bis-thiazoles and bis-1,3,4-thiadiazoles as anti-inflammatory, anti-ulcerogenic and analgesic agents.


Analgesics/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Ulcer Agents/pharmacology , Formazans/pharmacology , Thiazoles/pharmacology , Analgesics/chemical synthesis , Analgesics/chemistry , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Ulcer Agents/chemical synthesis , Anti-Ulcer Agents/chemistry , Dose-Response Relationship, Drug , Edema/drug therapy , Formazans/chemical synthesis , Formazans/chemistry , Male , Mice , Molecular Structure , Nociceptive Pain/drug therapy , Rats , Rats, Sprague-Dawley , Stomach Ulcer/drug therapy , Structure-Activity Relationship , Thiazoles/chemical synthesis , Thiazoles/chemistry
19.
PLoS One ; 9(2): e89169, 2014.
Article En | MEDLINE | ID: mdl-24586567

UNLABELLED: As a nutritional supplement, coenzyme Q10 (CoQ10) was tested previously in several models of diabetes and/or insulin resistance (IR); however, its exact mechanisms have not been profoundly explicated. Hence, the objective of this work is to verify some of the possible mechanisms that underlie its therapeutic efficacy. Moreover, the study aimed to assess the potential modulatory effect of CoQ10 on the antidiabetic action of glimebiride. An insulin resistance/type 2 diabetic model was adopted, in which rats were fed high fat/high fructose diet (HFFD) for 6 weeks followed by a single sub-diabetogenic dose of streptozotocin (35 mg/kg, i.p.). At the end of the 7(th) week animals were treated with CoQ10 (20 mg/kg, p.o) and/or glimebiride (0.5 mg/kg, p.o) for 2 weeks. CoQ10 alone opposed the HFFD effect and increased the hepatic/muscular content/activity of tyrosine kinase (TK), phosphatidylinositol kinase (PI3K), and adiponectin receptors. Conversely, it decreased the content/activity of insulin receptor isoforms, myeloperoxidase and glucose transporters (GLUT4; 2). Besides, it lowered significantly the serum levels of glucose, insulin, fructosamine and HOMA index, improved the serum lipid panel and elevated the levels of glutathione, sRAGE and adiponectin. On the other hand, CoQ10 lowered the serum levels of malondialdehyde, visfatin, ALT and AST. Surprisingly, CoQ10 effect surpassed that of glimepiride in almost all the assessed parameters, except for glucose, fructosamine, TK, PI3K, and GLUT4. Combining CoQ10 with glimepiride enhanced the effect of the latter on the aforementioned parameters. CONCLUSION: These results provided a new insight into the possible mechanisms by which CoQ10 improves insulin sensitivity and adjusts type 2 diabetic disorder. These mechanisms involve modulation of insulin and adiponectin receptors, as well as TK, PI3K, glucose transporters, besides improving lipid profile, redox system, sRAGE, and adipocytokines. The study also points to the potential positive effect of CoQ10 as an adds- on to conventional antidiabetic therapies.


Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Hypoglycemic Agents/pharmacology , Insulin Resistance , Membrane Proteins/metabolism , Transferases/metabolism , Ubiquinone/analogs & derivatives , Animals , Diabetes Mellitus, Experimental/enzymology , Drug Interactions , Glucose Transport Proteins, Facilitative/metabolism , Hypoglycemic Agents/therapeutic use , Liver/drug effects , Liver/metabolism , Male , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Nicotinamide Phosphoribosyltransferase/metabolism , Peroxidase/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Rats , Receptor for Advanced Glycation End Products , Receptor, Insulin/metabolism , Receptors, Adiponectin/metabolism , Receptors, Immunologic/chemistry , Receptors, Immunologic/metabolism , Ubiquinone/pharmacology , Ubiquinone/therapeutic use
...